Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
Multiple Myeloma Hub
Introduction
Exploring the impact of adding DEROTUMAM maintenance therapy to standard RVD induction therapy in transplant-eligible multiple myeloma patients, showing enhanced response rates and MRV negativity.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
